Vanda Pharmaceuticals (VNDA) Cash from Investing Activities (2010 - 2026)

Vanda Pharmaceuticals has reported Cash from Investing Activities for 17 years, with the latest figure at $20.2 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 53.91% year-over-year to $20.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $71.2 million (up 59.3% YoY) and the FY2025 annual result came in at $94.9 million, up 644.23% from the prior year.
• Cash from Investing Activities fell to $20.2 million in Q1 2026 per VNDA's latest filing, from $44.9 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $187.3 million in Q1 2023 and troughed at -$190.9 million in Q2 2023.
• A 5-year average of $8.0 million and a median of $10.9 million in 2022 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities jumped 15204.23% in 2022, then tumbled 1208.21% in 2023.
• Over 5 years, Cash from Investing Activities stood at $75.4 million in 2022, then slumped by 158.05% to -$43.8 million in 2023, then surged by 109.12% to $4.0 million in 2024, then soared by 1023.62% to $44.9 million in 2025, then slumped by 54.9% to $20.2 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $20.2 million, $44.9 million, and $21.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.